Advancing research on childhood cancer

LIH researcher awarded grant from the Fondatioun Kriibskrank Kanner

• Department of Cancer Research
• Tumor Immunotherapy and Microenvironment
• Donation

Dr Bassam Janji, head of the Tumor Immunotherapy and Microenvironment (TIME) research group within the Department of Cancer Research (DoCR) at the Luxembourg Institute of Health (LIH), has been awarded a new grant from the Fondatioun Kriibskrank Kanner. The funding will support his team’s ambitious project to develop and evaluate novel therapeutic strategies against high-risk neuroblastoma, one of the most aggressive forms of childhood cancer.

This collaboration was formalised through a partnership agreement signed between LIH and the Foundation on September 16th, in the presence of Mr Gaston Ternes, President of the Fondatioun Kriibskrank Kanner, Mr Pierre Dochen, Director of the Foundation, Prof. Dr Ulf Nehrbass, CEO of LIH, and Dr Frank Glod, Deputy CEO.

“This convention embodies our shared determination to put science at the service of life and to bring concrete answers to medical challenges that affect so many families around the world,” says Mr Ternes. By supporting Dr Janji’s research, the Foundation recognises the scientific excellence and innovation of LIH’s cancer research teams. It also highlights the Institute’s leading role in driving cutting-edge translational research that bridges the gap between laboratory discoveries and clinical impact.

We are deeply grateful to the Fondatioun Kriibskrank Kanner for their trust and generous support. This funding will allow us to pursue promising new approaches against high-risk neuroblastoma and, ultimately, bring hope to children and families affected by this devastating disease“, says Dr Janji.

Through this partnership, LIH and the Fondatioun Kriibskrank Kanner reaffirm their shared commitment to transforming pioneering research into tangible advances for young patients.